Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis
Heather Raglin, Editor
Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.
CONTACTS
Corporate:
Neal Koller
[email protected]
(410) 690-8687
Media:
Susan Thomas
[email protected]
(619) 540-9195